First medicine developed to treat MASH expected to be approved soon; Acadia’s Nuplazid fails as treatment for schizophrenia in Phase 3 study

Taking stock of the drug industry, from the lab to the medicine chest

March 12, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Madrigal Pharmaceuticals STAT+ | First medicine developed to treat MASH expected to be approved soon Resmetirom, a pill developed by Madrigal Pharmaceuticals, targets a protein in the liver that reduces liver fat, inflammation, and scarring. By Adam Feuerstein STAT+ | Acadia's Nuplazid fails as treatment for schizophrenia in Phase 3 study Currently approved to treat hallucinations associated with Parkinson's disease psychosis, the drug failed to do better than placebo in a late-stage clinical trial. By Adam Feuerstein Rigid rules at methadone clinics are jeopardizing patients' path to recovery from opioid addiction A STAT investigation shows that many addiction patients encounter indignities that would be unthinkable in any other health care setting. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser